Neuroinflammatory processes in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 11, Issue SUPPL. 1, 2005, Pages

  Hirsch, Etienne C ^a   Hunot, Stéphane ^a   Hartmann, Andreas ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Apoptosis; Cytokines; Dopamine neurons; Glial cells; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLSALICYLIC ACID; ANNONACIN; DICLOFENAC; IBUPROFEN; INDOMETACIN; LIPOPOLYSACCHARIDE; MELOXICAM; MINOCYCLINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PARACETAMOL; PIOGLITAZONE; ROTENONE; SALICYLIC ACID;

ASTROCYTOSIS; AUTOPSY; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL INFILTRATION; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; EPIDEMIOLOGICAL DATA; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GLIA CELL; HUMAN; IMMUNOCOMPETENT CELL; MICROGLIA; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ENCEPHALITIS; HUMANS; NEUROIMMUNOMODULATION; PARKINSON DISEASE;

EID: 18844374851     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2004.10.013     Document Type: Conference Paper

References (78)

1. C. Francois, C. Savy, C. Jan, D. Tande, E.C. Hirsch, and J. Yelnik Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson's disease patients J Comp Neurol 425 1 2000 121 129
2. C. Jan, C. Francois, D. Tande, J. Yelnik, L. Tremblay, Y. Agid, and E. Hirsch Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients Eur J Neurosci 12 12 2000 4525 4535
3. E.C. Hirsch, A.M. Graybiel, and Y. Agid Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease Nature 334 1988 345 348
4. H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2 2003 197 211
5. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 6 2003 889 909
6. P. Damier, E.C. Hirsch, P. Zhang, Y. Agid, and F. Javoy-Agid Glutathione peroxidase, glial cells and Parkinson's disease Neuroscience 52 1993 1 6
7. R.B. Banati, S.E. Daniel, and S.B. Blunt Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease Mov Disord 13 2 1998 221 227
8. B. Mirza, H. Hadberg, P. Thomsen, and T. Moos The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease Neuroscience 95 2 2000 425 432
9. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 1988 1285 1291
10. K. Parain, M.G. Murer, Q. Yan, B. Faucheux, Y. Agid, E. Hirsch, and R. Raisman-Vozari Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra Neuroreport 10 3 1999 557 561
11. L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, and F. Collins GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 5111 1993 1130 1132
12. E. Mayer, S.B. Dunnett, R. Pellitteri, and J.W. Fawcett Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons-I. Effects in vitro Neuroscience 56 2 1993 379 388
13. A.K. Cross, and M.N. Woodroofe Immunoregulation of microglial functional properties Microsc Res Tech 54 1 2001 10 17
14. S. Hunot, N. Dugas, B. Faucheux, A. Hartmann, M. Tardieu, P. Debre, Y. Agid, B. Dugas, and E.C. Hirsch Fc(epsilon)RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-a in glial cells J Neurosci 19 9 1999 3440 3447
15. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari Cytokines in Parkinson's disease J Neural Transm Suppl 58 2000 143 151
16. R.M. Bachoo, R.S. Kim, K.L. Ligon, E.A. Maher, C. Brennan, N. Billings, S. Chan, C. Li, D.H. Rowitch, W.H. Wong, and R.A. DePinho Molecular diversity of astrocytes with implications for neurological disorders Proc Natl Acad Sci USA 101 22 2004 8384 8389
17. K. Hisanaga, M. Asagi, Y. Itoyama, and Y. Iwasaki Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease Arch Neurol 58 10 2001 1580 1583
18. C.F. Orr, D.B. Rowe, and G.M. Halliday An inflammatory review of Parkinson's disease Prog Neurobiol 68 5 2002 325 340
19. U. Fiszer, E. Mix, S. Fredrikson, V. Kostulas, T. Olsson, and H. Link gamma delta+ T cells are increased in patients with Parkinson's disease J Neurol Sci 121 1 1994 39 45
20. M.R. Issidorides Neuronal vascular relationships in the zona compacta of normal and parkinsonian substantia nigra Brain Res 25 2 1971 289 299
21. B.A. Faucheux, A.M. Bonnet, Y. Agid, and E.C. Hirsch Blood vessels change in the mesencephalic of patients with Parkinson's disease Lancet 353 1999 981 982
22. B. Leveugle, B.A. Faucheux, C. Bouras, N. Nillesse, G. Spik, E.C. Hirsch, Y. Agid, and P.R. Hof Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases Acta Neuropathol (Berl) 91 6 1996 566 572
23. B.A. Faucheux, N. Nillesse, P. Damier, G. Spik, A. Mouatt-Prigent, A. Pierce, B. Leveugle, N. Kubis, J.J. Hauw, Y. Agid, and E.C. Hirsch Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease Proc Natl Acad Sci USA 92 21 1995 9603 9607
24. E.C. Hirsch, and B.A. Faucheux Iron metabolism and Parkinson's disease Mov Disord 13 Suppl. 1 1998 39 45
25. J.W. Langston, J.W. Ballard, J.W. Tetrud, and I. Irwin Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
26. J.W. Langston, L.S. Forno, J. Tetrud, A.G. Reeves, J.A. Kaplan, and D. Karluk Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure Ann Neurol 46 1999 598 605
27. H. Chen, S.M. Zhang, M.A. Hernan, M.A. Schwarzschild, W.C. Willett, G.A. Colditz, F.E. Speizer, and A. Ascherio Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease Arch Neurol 60 8 2003 1059 1064
28. R. Kruger, C. Hardt, F. Tschentscher, S. Jackel, W. Kuhn, T. Muller, J. Werner, D. Woitalla, D. Berg, N. Kuhnl, G.A. Fuchs, E.J. Santos, H. Przuntek, J.T. Epplen, L. Schols, and O. Riess Genetic analysis of immunomodulating factors in sporadic Parkinson's disease J Neural Transm 107 5 2000 553 562
29. I. Mizuta, M. Nishimura, E. Mizuta, S. Yamasaki, M. Ohta, S. Kuno, M. Nishimura, and M. Ota Relation between the high production related allele of the interferon-gamma (IFN-gamma) gene and age at onset of idiopathic Parkinson's disease in Japan J Neurol Neurosurg Psychiatry 71 6 2001 818 819
30. P.L. McGeer, K. Yasojima, and E.G. McGeer Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease Neurosci Lett 326 1 2002 67 69
31. K.M. Mattila, J.O. Rinne, T. Lehtimaki, M. Roytta, J.P. Ahonen, and M. Hurme Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients J Med Genet 39 6 2002 400 402
32. T. Schulte, L. Schols, T. Muller, D. Woitalla, K. Berger, and R. Kruger Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease Neurosci Lett 326 1 2002 70 72
33. J.C. Moller, C. Depboylu, H. Kolsch, F. Lohmuller, O. Bandmann, P. Gocke, Y. Du, S. Paus, U. Wullner, T. Gasser, W.H. Oertel, T. Klockgether, and R.C. Dodel Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease Neurosci Lett 359 3 2004 195 197
34. H. Akiyama, and P.L. McGeer Microglial response to 6-hydroxydopamine- induced substantia nigra lesions Brain Res 489 2 1989 247 253
35. Y. He, S. Appel, and W. Le Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum Brain Res 2001 187 193
36. A.M. Depino, C. Earl, E. Kaczmarczyk, C. Ferrari, H. Besedovsky, A. del Rey, F.J. Pitossi, and W.H. Oertel Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease Eur J Neurosci 18 10 2003 2731 2742
37. F. Cicchetti, A.L. Brownell, K. Williams, Y.I. Chen, E. Livni, and O. Isacson Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging Eur J Neurosci 15 6 2002 991 998
38. J.S. Schneider, and F.J. Denaro Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain J Neuropathol Exp Neurol 47 4 1988 452 458
39. G.T. Liberatore, V. JacksonLewis, S. Vukosavic, A.S. Mandir, M. Vila, W.G. McAuliffe, V.L. Dawson, T.M. Dawson, and S. Przedborski Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nature Med 5 12 1999 1403 1409
40. S. Sugama, L. Yang, B.P. Cho, L.A. DeGiorgio, S. Lorenzl, D.S. Albers, M.F. Beal, B.T. Volpe, and T.H. Joh Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice Brain Res 964 2 2003 288 294
41. I. Kurkowska-Jastrzebska, A. Wronska, M. Kohutnicka, A. Czlonkowski, and A. Czlonkowska The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse Exp Neurol 1999 50 61
42. P.L. McGeer, C. Schwab, A. Parent, and D. Doudet Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration Ann Neurol 54 5 2003 599 604
43. S.D. Hurley, M.K. O'Banion, D.D. Song, F.S. Arana, J.A. Olschowka, and S.N. Haber Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys Exp Neurol 184 2 2003 659 668
44. C. Barcia, A.S. Bahillo, E. Fernandez-Villalba, V. Bautista, M. Poza y Poza, A. Fernandez-Barreiro, E.C. Hirsch, and M.-T. Herrero Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys one year after MPTP exposure Glia 46 4 2004 402 409
45. A. Hartmann, S. Hunot, and E.C. Hirsch Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter Exp Neurol 184 2 2003 561 564
46. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 3 12 2000 1301 1306
47. G.U. Hoglinger, J. Feger, A. Prigent, P.P. Michel, K. Parain, P. Champy, M. Ruberg, W.H. Oertel, and E.C. Hirsch Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats J Neurochem 84 3 2003 491 502
48. N. Lapointe, M. St-Hilaire, M.G. Martinoli, J. Blanchet, P. Gould, C. Rouillard, and F. Cicchetti Rotenone induces non-specific central nervous system and systemic toxicity FASEB J 18 6 2004 717 719
49. E.C. Hirsch, G. Orieux, M-P. Muriel, C. Francois, and J. Feger Non dopaminergic neurons in Parkinson's disease Adv Neurol 91 2003 29 37
50. T.B. Sherer, R. Betarbet, C.M. Testa, B.B. Seo, J.R. Richardson, J.H. Kim, G.W. Miller, T. Yagi, A. Matsuno-Yagi, and J.T. Greenamyre Mechanism of toxicity in rotenone models of Parkinson's disease J Neurosci 23 34 2003 10756 10764
51. H.M. Gao, J. Jiang, B. Wilson, W. Zhang, J.S. Hong, and B. Liu Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease J Neurochem 81 6 2002 1285 1297
52. P. Champy, G.U. Hoglinger, J. Feger, C. Gleye, R. Hocquemiller, A. Laurens, V. Guerineau, O. Laprevote, F. Medja, A. Lombes, P.P. Michel, A. Lannuzel, E.C. Hirsch, and M. Ruberg Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe J Neurochem 88 1 2004 63 69
53. A.J. Herrera, A. Castano, J.L. Venero, J. Cano, and A. Machado The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system Neurobiol Dis 7 4 2000 429 447
54. A. Castano, A.J. Herrera, J. Cano, and A. Machado The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma J Neurochem 81 1 2002 150 157
55. Z.D. Ling, D.A. Gayle, J.W. Lipton, and P.M. Carvey Prenatal lipopolysaccharide alters postnatal dopamine in the laboratory rat T. Nagatsu T. Nabeshima R. McCarty D. Goldstein Catecholamine research: from molecular insights to clinical medicine 2002 Kluwer New York 209 212
56. P.M. Carvey, Q. Chang, J.W. Lipton, and Z. Ling Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease Front Biosci 8 2003 s826 s837
57. Z.D. Ling, Q. Chang, J.W. Lipton, C.W. Tong, T.M. Landers, and P.M. Carvey Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain Neuroscience 124 3 2004 619 628
58. H.M. Gao, B. Liu, W. Zhang, and J.S. Hong Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease FASEB J 17 13 2003 1954 1956
59. T. Dehmer, J. Lindenau, S. Haid, J. Dichgans, and J.B. Schulz Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo J Neurochem 74 5 2000 2213 2216
60. E. Rousselet, J. Callebert, K. Parain, C. Joubert, S. Hunot, A. Hartmann, C. Jacque, F. Perez-Diaz, C. Cohen-Salmon, J.M. Launay, and E.C. Hirsch Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP Exp Neurol 177 1 2002 183 192
61. K. Sriram, J.M. Matheson, S.A. Benkovic, D.B. Miller, M.I. Luster, and J.P. O'Callaghan Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease FASEB J 16 11 2002 1474 1476
62. C.K. Combs, D.E. Johnson, J.C. Karlo, S.B. Cannady, and G.E. Landreth Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists J Neurosci 20 2 2000 558 567
63. T. Breidert, J. Callebert, M.T. Heneka, G. Landreth, J.M. Launay, and E.C. Hirsch Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease J Neurochem 82 3 2002 615 624
64. S. Hunot, F. Boissiere, B. Faucheux, B. Brugg, A. Mouatt-Prigent, Y. Agid, and E.C. Hirsch Nitric oxide synthase and neuronal vulnerability in Parkinson's disease Neuroscience 72 2 1996 355 363
65. S. Hunot, M. Vila, P. Teismann, R.J. Davis, E.C. Hirsch, S. Przedborski, P. Rakic, and R.A. Flavell JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease Proc Natl Acad Sci USA 101 2 2004 665 670
66. T. Dehmer, M.T. Heneka, M. Sastre, J. Dichgans, and J.B. Schulz Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation J Neurochem 88 2 2004 494 501
67. P.J. Shughrue, R. Ransom, L. Warren, A. Vanko, B. West, K. Hoffman, G. Kinney, P. Meinke, and G. Seabrook Pioglitazone, but not a nonbrain penetrant PPARδ agonist, attenuates the loss of dopamine neurons from the mouse SNC after acute MPTP treatment Soc Neurosci 677 2004 10
68. B.M. Way, G. Lacan, W.P. Melega, A.A.F. DeSalles, and A. Pedroso Protective action of PPARδ agonist pioglitazone in a MPTP monkey model of Parkinson' disease Soc Neurosci 678 2004 22
69. D.C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D.K. Choi, H. Ischiropoulos, and S. Przedborski Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease J Neurosci 2002 1763 1771
70. E. Diguet, C.E. Gross, F. Tison, and E. Bezard Rise and fall of minocycline in neuroprotection: need to promote publication of negative results Exp Neurol 189 1 2004 1 4
71. E.C. Hirsch, T. Breidert, E. Rousselet, S. Hunot, A. Hartmann, and P.P. Michel The role of glial reaction and inflammation in Parkinson's disease H.J. Federoff R.E. Burke S. Fahn G. Fiskum Parkinson's disease: the life cycle of dopamine neuron vol. 991 2003 Ann NY Acad Sci 214 228
72. P. Teismann, K. Tieu, D.K. Choi, D.C. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, and S. Przedborski Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc Natl Acad Sci USA 100 9 2003 5473 5478
73. H. Mochizuki, K. Goto, H. Mori, and Y. Mizuno Histochemical detection of apoptosis in Parkinson's disease J Neurol Sci 137 1996 120 123
74. P. Anglade, S. Vyas, F. Javoy-Agid, M.T. Herrero, P.P. Michel, J. Marquez, A. Mouatt-Prigent, M. Ruberg, E.C. Hirsch, and Y. Agid Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease Histol Histopathol 12 1997 25 31
75. S. Wang, M. Miura, Y.K. Jung, H. Zhu, E. Li, and J. Yuan Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE Cell 92 4 1998 501 509
76. T. Furuya, H. Hayakawa, M. Yamada, K. Yoshimi, S. Hisahara, M. Miura, Y. Mizuno, and H. Mochizuki Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease J Neurosci 24 8 2004 1865 1872
77. A. Hartmann, J.D. Troadec, S. Hunot, K. Kikly, B.A. Faucheux, A. Mouatt-Prigent, M. Ruberg, Y. Agid, and E.C. Hirsch Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis J Neurosci 21 7 2001 2247 2255
78. G.W. Kreutzberg Microglia: a sensor for pathological events in the CNS Trends Neurosci 19 8 1996 312 318